The Effects on Metabolic Syndrome Parameters of Atypical Antipsychotic Agents in Schizophrenics Patients : 3 Years Retrospective Follow Up.

Bae, Ha Hyun; Yoon, Hai Joo; Park, Eun Kyung; Lee, Jong Il

doi:2017.20.1.5

Korean J Schizophr Res > Volume 20(1); 2017 > Article

Original Article

Korean Journal of Schizophrenia Research 2017;20(1):5-14.
DOI: https://doi.org/10.16946/kjsr.2017.20.1.5 Published online April 30, 2017.

The Effects on Metabolic Syndrome Parameters of Atypical Antipsychotic Agents in Schizophrenics Patients : 3 Years Retrospective Follow Up.

Ha Hyun Bae, Hai Joo Yoon, Eun Kyung Park, Jong Il Lee

¹Department of Psychiatry, National Center for Mental Health, Seoul, Korea. lji7542@naver.com
²Department of Clinical Psychology, National Center for Mental Health, Seoul, Korea.
³Department of Clinical Trial Center, Samsung Medical Center, Seoul, Korea.

Abstract

OBJECTIVES
Pharmacological treatment is critical on relapse prevention in patients with schizophrenia. However, atypical antipsychotic agents are known to cause weight gain more than typical agents despite their various effects. In addition, they are known to affect blood sugar, blood pressure, cholesterol, cardiac function, and sexual function. This study was designed to examine the effects on metabolic parameters when schizophrenic patients have been taken atypical antipsychotic agents.
METHODS
This was a trial in 137 patients with DSM-IV-TR schizophrenia who were admitted or treated in mental hospital. Anthropometric measurement and blood testing were conducted at baseline, 12 month, 36 month, and sociodemographic and treatment history were collected from medical records. We conducted height, weight, waist circumference, blood pressure, FBS, total cholesterol, HDL, triglyceride, and QTc interval. Metabolic syndrome was diagnosed by ATPIIIa criteria.
RESULTS
Aripiprazole showed the significant difference in the impact on weight, blood pressure, waist circumference, total cholesterol, HDL, triglyceride than paliperidone and olanzapine at 1-year and 3-year period. Olanzapine showed the significant increase of weight and triglyceride than paliperidone at 3-year period. The prevalence of metabolic syndrome increased in paliperidone at 1-year and in olanzapine at 3-year period compared to aripiprazole significantly.
CONCLUSION
We concluded that aripiprazole has less impact on the abdominal obesity, FBS, blood pressure, and cholesterol than paliperidone and olanzapine. Olanzapine showed the increase of long-term metabolic risk than other agents. There was needed the routine screening and multidisciplinary management of medical problems in schizophrenic patients for the prevention of metabolic syndrome.

Key Words: Schizophrenia · Atypical antipsychotics · Metabolic syndrome